These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 34156708)

  • 61. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
    Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
    Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
    Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers.
    Hou Y; Nitta H; Parwani AV; Li Z
    Hum Pathol; 2019 Apr; 86():108-114. PubMed ID: 30633926
    [TBL] [Abstract][Full Text] [Related]  

  • 64. PD-L1 expression in squamous cervical carcinomas of Mozambican women living with or without HIV.
    Lovane L; Tulsidás S; Carrilho C; Karlsson C
    Sci Rep; 2024 Jun; 14(1):12974. PubMed ID: 38839923
    [TBL] [Abstract][Full Text] [Related]  

  • 65. PD-L1 expression is an unfavourable prognostic indicator in Asian renal cell carcinomas.
    Yeong J; Zhao Z; Lim JCT; Li H; Thike AA; Koh VCY; Teh BT; Kanesvaran R; Toh CK; Tan PH; Khor LY
    J Clin Pathol; 2020 Aug; 73(8):463-469. PubMed ID: 31980560
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
    Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
    Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
    Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
    Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
    [TBL] [Abstract][Full Text] [Related]  

  • 68. High tumour mutational burden is associated with strong PD-L1 expression, HPV negativity, and worse survival in penile squamous cell carcinoma: an analysis of 165 cases.
    Hrudka J; Hojný J; Prouzová Z; Kendall Bártů M; Čapka D; Zavillová N; Matěj R; Waldauf P
    Pathology; 2024 Apr; 56(3):357-366. PubMed ID: 38161143
    [TBL] [Abstract][Full Text] [Related]  

  • 69. MMR deficient undifferentiated/dedifferentiated endometrial carcinomas showing significant programmed death ligand-1 expression (sp 142) with potential therapeutic implications.
    Hacking S; Jin C; Komforti M; Liang S; Nasim M
    Pathol Res Pract; 2019 Oct; 215(10):152552. PubMed ID: 31353229
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.
    Bulutay P; Eren ÖC; Özen Ö; Haberal AN; Kapucuoğlu N
    Turk J Obstet Gynecol; 2023 Sep; 20(3):164-173. PubMed ID: 37667475
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Association of cancer progression with elevated expression of programmed cell death protein 1 ligand 1 by upper tract urothelial carcinoma and increased tumor-infiltrating lymphocyte density.
    Nukui A; Kamai T; Arai K; Kijima T; Kobayashi M; Narimatsu T; Kambara T; Yuki H; Betsunoh H; Abe H; Fukabori Y; Yashi M; Yoshida KI
    Cancer Immunol Immunother; 2020 May; 69(5):689-702. PubMed ID: 32030476
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma.
    Lee HK; Kwon MJ; Ra YJ; Lee HS; Kim HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Choe JY; Min KW; Kang SY
    Diagn Pathol; 2020 Oct; 15(1):126. PubMed ID: 33054840
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Association of the programmed death ligand-1 combined positive score in tumors and clinicopathological features in esophageal cancer.
    Huang Z; Jin Y; Cai X; Chen L; Shen X; Li B; Chen H; Li Y
    Thorac Cancer; 2022 Feb; 13(4):523-532. PubMed ID: 34953041
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Immune classification for the PD-L1 expression and tumour-infiltrating lymphocytes in colorectal adenocarcinoma.
    Noh BJ; Kwak JY; Eom DW
    BMC Cancer; 2020 Jan; 20(1):58. PubMed ID: 31992245
    [TBL] [Abstract][Full Text] [Related]  

  • 76. PD-L1: Can it be a biomarker for the prognosis or a promising therapeutic target in cervical cancer?
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2022 Feb; 103():108484. PubMed ID: 34954558
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Significant association of PD-L1 expression with human papillomavirus positivity and its prognostic impact in oropharyngeal cancer.
    Hong AM; Ferguson P; Dodds T; Jones D; Li M; Yang J; Scolyer RA
    Oral Oncol; 2019 May; 92():33-39. PubMed ID: 31010620
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
    Balermpas P; Rödel F; Krause M; Linge A; Lohaus F; Baumann M; Tinhofer I; Budach V; Sak A; Stuschke M; Gkika E; Grosu AL; Abdollahi A; Debus J; Stangl S; Ganswindt U; Belka C; Pigorsch S; Multhoff G; Combs SE; Welz S; Zips D; Lim SY; Rödel C; Fokas E;
    Int J Cancer; 2017 Aug; 141(3):594-603. PubMed ID: 28480996
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Comparison of PD-L1 expression and MMR status between primary and matched metastatic lesions in patients with cervical cancer.
    Liu H; Sun L; Lian J; Wang L; Xi Y; Zhao G; Wang J; Lan X; Du H; Yan W; Bu P; Wang P; Moore A; Zhao H
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11397-11410. PubMed ID: 37378674
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.